This article is more than 5 years old. Information may no longer be current.
Combination of subconjunctival, intracorneal bevacizumab reduces corneal neovascularization
Cornea. 2011;30(10):1110-1114
Click Here to Manage Email Alerts
A study examining the use of combined subconjunctival and intracorneal injections of bevacizumab found a reduction in the neovascularized area for all patients.
The chart review included 12 eyes of 12 consecutive patients who received both types of injections — one to three injections of 2.5 mg bevacizumab (1.25 mg/0.05 mL subconjunctival and 1.25 mg/0.05 mL intrastromal) — between October 2007 and August 2010.
After a follow-up period 0.25 to 22 months (mean: 6.4 months), all patients showed a partial regression in corneal vessels demonstrated by a reduction in vessel number, caliber and lipid deposition, according to the study. No intraoperative or postoperative complications were recorded.
"Our findings suggest that combined subconjunctival and intracorneal bevacizumab may be an effective alternative in treating corneal neovascularization by addressing both peripheral and central vessels," the study authors wrote. "Bevacizumab also may be considered as an adjunct to other medications or procedures for the treatment of corneal neovascularization."
The authors recommended that future research determine the number of injections per eye for maximal effect, the dosing schedule, the most efficient route of administration and safety.